{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T05:57:30Z","timestamp":1784354250127,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologe"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00292-020-00831-7","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T16:05:56Z","timestamp":1601309156000},"page":"582-588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Anwendungen der FISH in der Diagnostik von Lungenkarzinomen","Application of FISH in the diagnosis of lung cancer"],"prefix":"10.1007","volume":"41","author":[{"given":"Lena","family":"Hieggelke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Schultheis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,28]]},"reference":[{"key":"831_CR1","unstructured":"Agency EM (2012) Eur Med Agency. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/xalkori-epar-public-assessment-report_en.pdf. Zugegriffen: 18. April 2020"},{"key":"831_CR2","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41379-018-0182-8","volume":"32","author":"R Castiglione","year":"2019","unstructured":"Castiglione\u00a0R, Alidousty\u00a0C, Holz\u00a0B et al (2019) Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies. Mod Pathol 32:627\u2013638","journal-title":"Mod Pathol"},{"key":"831_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jtho.2016.10.014","volume":"12","author":"A Drilon","year":"2017","unstructured":"Drilon\u00a0A, Cappuzzo\u00a0F, Ou\u00a0S\u2011HI et al (2017) Targeting MET in lung cancer: Will expectations finally be MET? J\u00a0Thorac Oncol 12:15\u201326","journal-title":"J Thorac Oncol"},{"key":"831_CR4","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman\u00a0JA, Zejnullahu\u00a0K, Mitsudomi\u00a0T et\u00a0al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039\u20131043","journal-title":"Science"},{"key":"831_CR5","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","volume":"6","author":"JF Gainor","year":"2016","unstructured":"Gainor\u00a0JF, Dardaei\u00a0L, Yoda\u00a0S et al (2016) Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 6:1118\u20131133","journal-title":"Cancer Discov"},{"key":"831_CR6","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.tranon.2019.02.015","volume":"12","author":"A Guyard","year":"2019","unstructured":"Guyard\u00a0A, Charpy\u00a0C, Th\u00e9ou-Anton\u00a0N et al (2019) Isolated 5\u2032 signals are an atypical pattern to be considered as positive for ALK rearrangement: a brief report of three cases and review of the literature. Transl Oncol 12:784\u2013787","journal-title":"Transl Oncol"},{"key":"831_CR7","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1097\/PAS.0000000000000911","volume":"41","author":"JF Hechtman","year":"2017","unstructured":"Hechtman\u00a0JF, Benayed\u00a0R, Hyman\u00a0DM et al (2017) Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol 41:1547\u20131551","journal-title":"Am J Surg Pathol"},{"key":"831_CR8","doi-asserted-by":"publisher","first-page":"iii25","DOI":"10.1093\/annonc\/mdw303","volume":"Suppl 3","author":"C Heydt","year":"2016","unstructured":"Heydt C, Kostenko A, Merkelbach-Bruse S et al (2016) ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology. Ann Oncol. Suppl 3:iii25\u2013iii34. https:\/\/doi.org\/10.1093\/annonc\/mdw303. PMID:27573753","journal-title":"Ann Oncol"},{"key":"831_CR9","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jmoldx.2019.06.006","volume":"21","author":"C Heydt","year":"2019","unstructured":"Heydt\u00a0C, Ruesseler\u00a0V, Pappesch\u00a0R et al (2019) Comparison of in situ and extraction-based methods for the detection of ROS1 rearrangements in solid tumors. J\u00a0Mol Diagnostics 21:971\u2013984","journal-title":"J Mol Diagnostics"},{"key":"831_CR10","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.3390\/cancers6031540","volume":"6","author":"H Kawakami","year":"2014","unstructured":"Kawakami\u00a0H, Okamoto\u00a0I, Okamoto\u00a0W et\u00a0al (2014) Targeting MET amplification as a\u00a0new oncogenic driver. Cancers 6:1540\u20131552","journal-title":"Cancers"},{"key":"831_CR11","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1111\/cas.12275","volume":"104","author":"T Kohno","year":"2013","unstructured":"Kohno\u00a0T, Tsuta\u00a0K, Tsuchihara\u00a0K et\u00a0al (2013) RET fusion gene: translation to personalized lung cancer therapy. Cancer Sci 104:1396\u20131400","journal-title":"Cancer Sci"},{"key":"831_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1158\/0008-5472.CAN-05-2749","volume":"66","author":"M Kong-Beltran","year":"2006","unstructured":"Kong-Beltran\u00a0M, Seshagiri\u00a0S, Zha\u00a0J et al (2006) Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 66:283\u2013289","journal-title":"Cancer Res"},{"key":"831_CR13","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak\u00a0EL, Bang\u00a0YJ, Camidge\u00a0DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N\u00a0Engl J Med 363:1693\u20131703","journal-title":"N Engl J Med"},{"key":"831_CR14","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/modpathol.2014.107","volume":"28","author":"SE Lee","year":"2015","unstructured":"Lee\u00a0SE, Lee\u00a0B, Hong\u00a0M et\u00a0al (2015) Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma. Mod Pathol 28:468\u2013479","journal-title":"Mod Pathol"},{"key":"831_CR15","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1200\/JCO.2017.76.2294","volume":"36","author":"JJ Lin","year":"2018","unstructured":"Lin\u00a0JJ, Zhu\u00a0VW, Yoda\u00a0S et al (2018) Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer. J\u00a0Clin Oncol 36:1199\u20131206","journal-title":"J Clin Oncol"},{"key":"831_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","volume":"142","author":"NI Lindeman","year":"2018","unstructured":"Lindeman\u00a0NI, Cagle\u00a0PT, Aisner\u00a0DL et\u00a0al (2018) Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted Tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med 142:321\u2013346","journal-title":"Arch Pathol Lab Med"},{"issue":"9","key":"831_CR17","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/annonc\/mdz204","volume":"30","author":"C Marchi\u00f2","year":"2019","unstructured":"Marchi\u00f2 C, Scaltriti M, Ladanyi M et\u00a0al (2019) ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol 30(9):1417\u20131427. https:\/\/doi.org\/10.1093\/annonc\/mdz204. PMID:31268127","journal-title":"Ann Oncol"},{"issue":"3","key":"831_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.21037\/tlcr-19-339","volume":"9","author":"TR Overbeck","year":"2020","unstructured":"Overbeck TR, Cron DA, Schmitz K et\u00a0al (2020) Top-level MET gene copy number gain defines a\u00a0subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis. Transl Lung Cancer Res 9(3):603\u2013616. https:\/\/doi.org\/10.21037\/tlcr-19-339. PMID:32676323; PMCID:PMC7354108","journal-title":"Transl Lung Cancer Res"},{"key":"831_CR19","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez\u00a0JG, Janne\u00a0PA, Lee\u00a0JC et\u00a0al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497\u20131500","journal-title":"Science"},{"key":"831_CR20","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard\u00a0D, Popat\u00a0S, Kerr\u00a0K et al (2018) Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv192\u2013iv237","journal-title":"Ann Oncol"},{"key":"831_CR21","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1158\/1078-0432.CCR-14-0450","volume":"21","author":"H-U Schildhaus","year":"2015","unstructured":"Schildhaus\u00a0H\u2011U, Schultheis\u00a0AM, R\u00fcschoff\u00a0J et al (2015) MET amplification status in therapy-Na\u00efve Adeno- and Squamous cell carcinomas of the lung. Clin Cancer Res 21:907\u2013915","journal-title":"Clin Cancer Res"},{"key":"831_CR22","first-page":"80","volume":"143","author":"G Smuk","year":"2020","unstructured":"Smuk\u00a0G, Pajor\u00a0G, Szuhai\u00a0K et\u00a0al (2020) Attenuated isolated 3\u2032 signal: a highly challenging therapy relevant ALK FISH pattern in NSCLC. Cancer Treat Res 143:80\u201385","journal-title":"Cancer Treat Res"},{"key":"831_CR23","unstructured":"Society AC (2020) Key statistics for lung cancer\/What is lung cancer? https:\/\/www.cancer.org\/cancer\/lung-cancer\/about\/key-statistics.html. Zugegriffen: 18. April 2020"},{"key":"831_CR24","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda\u00a0M, Choi\u00a0YL, Enomoto\u00a0M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561\u2013566","journal-title":"Nature"},{"key":"831_CR25","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/2159-8290.CD-12-0108","volume":"2","author":"K Takezawa","year":"2012","unstructured":"Takezawa\u00a0K, Pirazzoli\u00a0V, Arcila\u00a0ME et al (2012) HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR T790M mutation. Cancer Discov 2:922\u2013933","journal-title":"Cancer Discov"},{"key":"831_CR26","volume-title":"IASLC Atlas of ALK and ROS1 testing in lung cancer","author":"MS Tsao","year":"2016","unstructured":"Tsao\u00a0MS, Hirsch\u00a0FR, Yatabe\u00a0Y et\u00a0al (2016) IASLC Atlas of ALK and ROS1 testing in lung cancer. Editorial Rx Press, Aurora, Colorado"},{"key":"831_CR27","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/bjc.2014.36","volume":"110","author":"K Tsuta","year":"2014","unstructured":"Tsuta\u00a0K, Kohno\u00a0T, Yoshida\u00a0A et al (2014) RET-rearranged non-small-cell lung carcinoma: a\u00a0clinicopathological and molecular analysis. Br J Cancer 110:1571\u20131578","journal-title":"Br J Cancer"},{"key":"831_CR28","first-page":"S719","volume":"13","author":"W Wang","year":"2018","unstructured":"Wang\u00a0W, Xu\u00a0C, Zhu\u00a0Y et al (2018) P2.03-09 the real world of NTRK fusion data in the Chinese lung cancer populations: a multicenter study. J\u00a0Thorac Oncol 13:S719","journal-title":"J Thorac Oncol"},{"key":"831_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jtho.2016.08.137","volume":"12","author":"M Wiesweg","year":"2017","unstructured":"Wiesweg\u00a0M, Eberhardt\u00a0WEE, Reis\u00a0H et al (2017) High prevalence of concomitant oncogene mutations\u00a0in prospectively identified patients with\u00a0ROS1-positive metastatic lung cancer. J\u00a0Thorac Oncol 12:54\u201364","journal-title":"J Thorac Oncol"},{"key":"831_CR30","doi-asserted-by":"publisher","first-page":"9004","DOI":"10.1200\/JCO.2019.37.15_suppl.9004","volume":"37","author":"J Wolf","year":"2019","unstructured":"Wolf\u00a0J, Seto\u00a0T, Han\u00a0J\u2011Y et al (2019) Capmatinib (INC280) in MET\u2206ex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1\u00a0study. J\u00a0Clin Oncol 37:9004\u20139004","journal-title":"J Clin Oncol"}],"container-title":["Der Pathologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-020-00831-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-020-00831-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-020-00831-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T01:24:31Z","timestamp":1632792271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-020-00831-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,28]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["831"],"URL":"https:\/\/doi.org\/10.1007\/s00292-020-00831-7","relation":{},"ISSN":["0172-8113","1432-1963"],"issn-type":[{"value":"0172-8113","type":"print"},{"value":"1432-1963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,28]]},"assertion":[{"value":"28 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"L.\u00a0Hieggelke und A.\u00a0M.\u00a0Schultheis geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}